Premium
Immunotherapy for Invasive Fungal Infections in Transplant Patients: Back to the Future?
Author(s) -
Hirsch Hans H.,
Hartmann Anders
Publication year - 2010
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2010.03189.x
Subject(s) - caspofungin , medicine , echinocandin , micafungin , anidulafungin , intensive care medicine , posaconazole , salvage therapy , voriconazole , esophageal candidiasis , organ transplantation , fluconazole , transplantation , immunology , antifungal , dermatology , chemotherapy , human immunodeficiency virus (hiv) , viral disease
For kidney transplant patients with life‐threatening disseminated fungal infections and failure of modern antifungal therapies, exogenous interferon‐gamma might represent an adjunct salvage therapy, but the risk‐benefit ratio is not yet established.
See Article by Armstrong‐James et al on page 1796.